Arista Wealth Management LLC Takes Position in Edwards Lifesciences Corporation $EW

Arista Wealth Management LLC acquired a new stake in Edwards Lifesciences Corporation (NYSE:EW) in the second quarter, Holdings Channel reports. The institutional investor acquired 2,928 shares of the medical research company’s stock, valued at approximately $229,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC increased its holdings in Edwards Lifesciences by 0.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock valued at $2,170,000 after purchasing an additional 145 shares during the last quarter. Pacific Capital Partners Ltd bought a new stake in Edwards Lifesciences in the second quarter valued at about $1,760,000. Czech National Bank increased its holdings in Edwards Lifesciences by 5.8% in the second quarter. Czech National Bank now owns 143,385 shares of the medical research company’s stock valued at $11,214,000 after purchasing an additional 7,917 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in Edwards Lifesciences by 13.5% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company’s stock valued at $5,582,000 after purchasing an additional 9,188 shares during the last quarter. Finally, Mirova US LLC increased its holdings in Edwards Lifesciences by 56.2% in the second quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock valued at $229,257,000 after purchasing an additional 1,054,301 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Up 2.5%

Shares of Edwards Lifesciences stock opened at $74.50 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The company has a market capitalization of $43.74 billion, a P/E ratio of 10.72, a price-to-earnings-growth ratio of 3.49 and a beta of 1.05. The business has a 50-day moving average of $77.54 and a two-hundred day moving average of $76.16. Edwards Lifesciences Corporation has a 1 year low of $64.89 and a 1 year high of $83.00.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.05. The company had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.Edwards Lifesciences’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, equities analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Wall Street Analyst Weigh In

EW has been the subject of a number of recent analyst reports. Robert W. Baird upped their price objective on Edwards Lifesciences from $78.00 to $79.00 and gave the company a “neutral” rating in a report on Friday, July 25th. Wall Street Zen downgraded Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a report on Monday, September 29th. Daiwa America upgraded Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 29th. Barclays increased their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, July 25th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, October 8th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average price target of $87.06.

Insider Activity

In other news, VP Daniel J. Lippis sold 4,114 shares of the company’s stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider directly owned 206,900 shares of the company’s stock, valued at $16,150,614. This represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.